Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21424366 | 0.80 | TSHR (0.34) | LMNA | |
| SCHEMBL25801704 | 0.78 | — | — | |
| SCHEMBL26750304 | 0.76 | — | — | |
| SCHEMBL23513672 | 0.74 | GPR84 (0.50) | CA1ACE2 | |
| SCHEMBL26388832 | 0.73 | ALOX15 (0.33) | — | |
| SCHEMBL25847062 | 0.72 | CA2 (0.35) | TP53CA1ACE2FDPS | |
| SCHEMBL20792042 | 0.71 | CA1 (0.50) | TP53OPRM1CA1SPHK1LMNA | |
| Hydrochloric Acid SCHEMBL3117717 | 0.69 | LMNA (0.39) | SPHK1LMNAFDPS | |
| SCHEMBL7368657 | 0.69 | CA2 (0.45) | CA1ACE2 | |
| SCHEMBL25898172 | 0.69 | HDAC7 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210346509-A1 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof | ASTRAZENECA AB (SE) | 2021-11-11 | — | — | US | disclosed |
| US-20200390895-A1 | UNIVERSAL ABT COMPOUNDS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. | 2020-12-17 | — | — | US | disclosed |
| US-20200268898-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | IONIS PHARMACEUTICALS, INC. | 2020-08-27 | — | — | US | disclosed |
| US-20190134214-A1 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof | ASTRAZENECA AB (SE) | 2019-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134214-A1 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof | GLP1R, GIPR, GRPR | TP53 3483/4885OPRM1 695/4885CA1 1652/4885 |
| US-20210346509-A1 | GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses Thereof | GLP1R, GIPR, GRPR | TP53 3483/4885OPRM1 695/4885CA1 1652/4885 |
| US-20200268898-A1 | GLP-1 RECEPTOR LIGAND MOIETY CONJUGATED OLIGONUCLEOTIDES AND USES THEREOF | GLP1R, GIPR, GRPR | TP53 3483/4885OPRM1 695/4885CA1 1652/4885 |
| US-20200390895-A1 | UNIVERSAL ABT COMPOUNDS AND USES THEREOF | CD47, MCL1, BCL9 | TP53 27/4885OPRM1 4149/4885CA1 3648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.